NASDAQ:ACHN Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free ACHN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.79▼$0.8050-Day Range$6.76▼$6.7652-Week Range$2.06▼$7.01Volume1,910 shsAverage Volume8.44 million shsMarket Capitalization$110.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Achillion Pharmaceuticals alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Achillion Pharmaceuticals Stock (NASDAQ:ACHN)Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… ACHN Stock News HeadlinesMarch 30, 2024 | benzinga.comKim P. Kamdar's Net WorthMay 20, 2023 | fool.comLexicon Pharmaceuticals (NASDAQ: LXRX)April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 19, 2023 | thestreet.comGilead Sciences Buying Achillion Was Twitter Speculation at Its FinestSeptember 18, 2022 | investing.comACHN_old Historical DataJanuary 13, 2022 | thestreet.comWhy Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading TodayJanuary 12, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: Here's Next Week's Game PlanSee More Headlines Receive ACHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHN CUSIP00448Q20 CIK1070336 Webwww.achillion.com Phone203-624-7000FaxN/AEmployees56Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.95% Return on Assets-29.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book0.41Miscellaneous Outstanding Shares140,047,000Free FloatN/AMarket Cap$110.80 million OptionableOptionable Beta1.59 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Joseph Truitt (Age 54)Pres, CEO & Director Ms. Martha E. Manning (Age 64)Exec. VP, Gen. Counsel & Corp. Sec. Mr. Brian R. Di Donato (Age 52)CFO, SVP & Treasurer Mr. Paul Firuta (Age 53)Exec. VP & COO Dr. Kevin P. MalobiskySr. VP of Regulatory Affairs, Quality & ComplianceKey CompetitorsEmergent BioSolutionsNYSE:EBSRegulus TherapeuticsNASDAQ:RGLSBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIORigel PharmaceuticalsNASDAQ:RIGLView All Competitors ACHN Stock Analysis - Frequently Asked Questions How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. What other stocks do shareholders of Achillion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP). This page (NASDAQ:ACHN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achillion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
